Tasquinimod is primarily investigated for its anti-cancer properties, particularly in the treatment of solid tumors such as prostate cancer. It functions as an inhibitor of the tumor microenvironment by targeting proteins like S100A9, which play a role in inflammation, angiogenesis, and immune suppression associated with cancer progression. By modulating these pathways, tasquinimod helps suppress tumor growth and metastasis. It has shown promise in clinical trials for advanced prostate cancer, where it demonstrated the ability to prolong progression-free survival. Its mechanism includes disrupting the interaction between tumor cells and surrounding stromal cells, thereby limiting the support structures tumors need to grow and spread. Additionally, tasquinimod exhibits immunomodulatory effects, enhancing anti-tumor immune responses by reducing the accumulation of myeloid-derived suppressor cells (MDSCs) in the tumor environment. This makes it a potential candidate for combination therapies with other immunotherapies or conventional treatments like chemotherapy and radiation. Research is ongoing to explore its efficacy in other cancers and chronic inflammatory conditions where angiogenesis and immune modulation are key factors.